Is the Surgical View of Breast Cancer Coming to an End?

Breast cancer is a systemic disease, although most patients are diagnosed at early stages described as “localized” (stage I through stage III). Breast cancer being systemic means that, even if detected when the tumor is only 1-2 cm, cancer cells may spread around it, to axillary lymph nodes, or systemically at a microscopic scale. Macroscopic (visible) tumors contain tens of millions of cancer cells, while microscopic (invisible) tumor clusters may contain tens of thousands to millions of cells. Breast cancer’s potential microscopic spread depends on age, tumor size, lymph node metastasis, tumor genetics, grade, hormone receptor status, and HER2 status.
Changing the Terms “Mastectomy” and “Partial Mastectomy”
The terms describing surgical removal of breast tissue, mastectomy and partial mastectomy , do not accurately reflect breast cancer’s surgical goal and underlying biology, often confusing patients. To clarify surgical intent and improve education, adherence, and perception, these terms should include the expression macroscopic debulking . Debulking surgery means an operation reducing tumor volume.
“Mastectomy,” surgical removal of the breast, was first clearly described and performed in 1882 by Dr. William Halsted (see the history of breast cancer). Other types were later adopted. Today, the most common is partial mastectomy, removing the tumor with surrounding normal breast tissue, also called lumpectomy , and these operations are generally considered breast-conserving surgery .
We now know that breast cancer is a systemic disease with varying potential for microscopic spread depending on clinicopathological factors such as age, tumor size, lymph node metastasis, tumor genetics, grade, hormone receptor and HER2 status. In other words, after mastectomy or lumpectomy, there is a substantial possibility of microscopic cancer remaining regionally or systemically. To reduce this likelihood, neoadjuvant (preoperative tumor-shrinking) and adjuvant (postoperative protective) treatments are frequently used. Adjuvant radiotherapy is designed to eliminate micrometastatic deposits remaining after lumpectomy. Adjuvant chemotherapy and hormonal therapy are designed for systemically spread micrometastatic disease.
The terms mastectomy and partial mastectomy have not been updated for decades and should be called “macroscopic debulking mastectomy” and “macroscopic debulking partial mastectomy” to reflect modern practice. The added description “macroscopic debulking” addresses removal of the visible (oncological imaging methods can detect it) primary tumor at the macroscopic level, implying that a significant possibility of microscopic cancer cells still remains.
Related Topic:
This Change in Terminology May Clarify Treatment Plans for Patients
Adding “macroscopic debulking” (surgical removal of visible tumors) would improve patient education, clarity of treatment plans, and perhaps adherence. Using mastectomy or partial mastectomy alone gives the impression that all breast cancer cells have been removed from the body. Patients often ask: “If my tumor has been removed, why do I need adjuvant chemotherapy, hormonal therapy, or radiation therapy?” Patients should be informed that breast cancer is systemic, can spread microscopically, and may require other adjuvant treatments after surgery. They should also understand that the likelihood of microscopic spread varies according to age, stage, grade, receptor status, and genomic factors.
Two Examples
For example, a patient with a 6 cm breast tumor and ipsilateral axillary lymph node involvement (pathological stage T3N1), with estrogen receptor-negative, progesterone receptor-negative, HER2 receptor-negative (that is, triple-negative) breast cancer, definitely needs radiotherapy and chemotherapy after axillary node removal and macroscopic debulking lumpectomy. Alternatively, a patient with a 7 mm tumor but no axillary node involvement or distant metastasis (pathological T1bN0M0), with estrogen receptor-negative, progesterone receptor-negative, HER2-positive breast cancer should receive adjuvant anti-HER2 treatment for up to 1 year after macroscopic debulking mastectomy to address potentially pre-existing micrometastatic disease.
Related Topic:
Other Benefits of Changing the View of Breast Cancer Surgery
Educating patients about macroscopic debulking may save physicians time explaining the rationale for adjuvant chemotherapy, hormonal therapy, and radiotherapy. Before clinic visits, educational leaflets may be provided or patients directed to reputable educational websites explaining macroscopic debulking and systemic cancer eradication through various methods. If patients perceive breast cancer as a systemic disease capable of microscopic spread and understand that surgery may not generally eliminate all cancer completely, their expectations and perhaps adherence to adjuvant treatment improve. Finally, “macroscopic debulking” applies not only to breast cancer but also to many other cancers (for example, ovarian cancer).
Sources
Breast Cancer Surgical Terminology Should Be Updated to Reflect Modern Medical Practice
ascopost.com - 10 February 2019
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.